𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor – a randomized placebo-controlled study in patients with chronic hepatitis C

✍ Scribed by M. L. SHIFFMAN; P. POCKROS; J. G. MCHUTCHISON; E. R. SCHIFF; M. MORRIS; G. BURGESS

Book ID
108605888
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
287 KB
Volume
31
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Robust antiviral activity of R1626, a no
Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C
✍ Stuart K. Roberts; Graham Cooksley; Gregory J. Dore; Richard Robson; David Shaw; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 511 KB

The nucleoside analog R1479 is a potent and highly selective inhibitor of nonstructural protein 5B-directed hepatitis C virus (HCV) replication in vitro. R1626, a tri-isobutyl ester prodrug of R1479, was developed to increase bioavailability and improve antiviral activity. A multicenter, observer-bl

Efficacy and safety of golimumab in pati
Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial
✍ Robert D. Inman; John C. Davis Jr.; Désirée Van Der Heijde; Laura Diekman; Joach 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 2 views

## Abstract ## Objective To evaluate the efficacy and safety of golimumab in patients with ankylosing spondylitis (AS) in the GO‐RAISE study. ## Methods Patients with active AS, a Bath AS Disease Activity Index (BASDAI) score ≥4, and a back pain score of ≥4 were randomly assigned in a 1.8:1.8:1